Friday, 16 October 2026European Markets

THUNDERBIRD Stock Is 32% Up In The Last 21 Sessions

Loading stream...

Thunderbird Resorts Inc. (AEX-Index: TBIRD.AS) shares have been making waves in the stock market. In a period of just 21 trading sessions, there was an astounding 32.45% gain, with the shares increasing from EUR0.08 to EUR0.10 as of Tuesday morning trading. Interestingly, this rise followed a downward trend in the previous session, signaling a remarkable turnaround in Thunderbird's performance.

About Thunderbird Resorts

Based in Panama, Thunderbird Resorts is a company that has diversified into gaming, hospitality and real estate. It has a significant presence across Nicaragua and Peru, where it operates three slot parlors and three casinos, and has 630 gaming positions. The company also runs operations across those three regions.

Financial Performance

Despite TBIRD.AS's impressive performance, it's important to take a closer look at its fundamentals. Thunderbird boasts a trailing 12-month Earnings per Share of EUR0.01, signifying modest profitability. Its PE (Price to Earnings) Ratio stands at 10.2, suggesting that an investor is investing EUR10.2 for every euro earned. This high PE Ratio may be an indication that investors anticipate more growth from Thunderbird in the future.

Trading Volume

Thunderbird last reported a trading volume of 216,922 shares. This figure is an indication of diminished trading interest over recent times, which is a trend to closely observe.

Emerging Player in the Market

As the AEX-Index, where TBIRD.AS is listed, continues to decline by 0.08% to EUR772.13, it is important for investors to keep an eye on this emerging player in the gaming and hospitality industries. Thunderbird's ability to buck trends during its current bull run is notable. It underscores the often volatile nature of stock markets and at the same time, the possible rewards of investing despite the associated risks.

More news about THUNDERBIRD (TBIRD.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com